Eric B Meltzer

Summary

Affiliation: Duke University Medical Center
Country: USA

Publications

  1. ncbi Idiopathic pulmonary fibrosis
    Eric B Meltzer
    Department of Medicine, Division of Pulmonary, Allergy and Critical Care, Duke University Medical Center, Durham, North Carolina 27710, USA
    Orphanet J Rare Dis 3:8. 2008
  2. ncbi ?-arrestin deficiency protects against pulmonary fibrosis in mice and prevents fibroblast invasion of extracellular matrix
    Alysia Kern Lovgren
    Division of Pulmonary, Allergy, and Critical Care Medicine, Department of Medicine, Duke University Medical Center, Durham, NC 27710, USA
    Sci Transl Med 3:74ra23. 2011
  3. ncbi Severe lung fibrosis requires an invasive fibroblast phenotype regulated by hyaluronan and CD44
    Yuejuan Li
    Division of Pulmonary, Allergy, and Critical Care Medicine, Department of Medicine, Duke University School of Medicine, Durham, NC 27710, USA
    J Exp Med 208:1459-71. 2011
  4. ncbi Bayesian probit regression model for the diagnosis of pulmonary fibrosis: proof-of-principle
    Eric B Meltzer
    Department of Medicine, Division of Pulmonary, Allergy and Critical Care Medicine, Duke University Medical Center, Durham, North Carolina, USA
    BMC Med Genomics 4:70. 2011
  5. ncbi Inhibition of pulmonary fibrosis in mice by CXCL10 requires glycosaminoglycan binding and syndecan-4
    Dianhua Jiang
    Division of Pulmonary, Allergy, and Critical Care Medicine, Department of Medicine, Duke University School of Medicine, Durham, North Carolina 27710, USA
    J Clin Invest 120:2049-57. 2010

Collaborators

Detail Information

Publications5

  1. ncbi Idiopathic pulmonary fibrosis
    Eric B Meltzer
    Department of Medicine, Division of Pulmonary, Allergy and Critical Care, Duke University Medical Center, Durham, North Carolina 27710, USA
    Orphanet J Rare Dis 3:8. 2008
    ..Meanwhile, pulmonary transplantation remains a viable option for patients with IPF. It is expected that, during the next decade, considerable progress will be made toward the understanding and treatment of this devastating illness...
  2. ncbi ?-arrestin deficiency protects against pulmonary fibrosis in mice and prevents fibroblast invasion of extracellular matrix
    Alysia Kern Lovgren
    Division of Pulmonary, Allergy, and Critical Care Medicine, Department of Medicine, Duke University Medical Center, Durham, NC 27710, USA
    Sci Transl Med 3:74ra23. 2011
    ..These data implicate ?-arrestins as mediators of fibroblast invasion and the development of pulmonary fibrosis, and as a potential target for therapeutic intervention in patients with idiopathic pulmonary fibrosis...
  3. ncbi Severe lung fibrosis requires an invasive fibroblast phenotype regulated by hyaluronan and CD44
    Yuejuan Li
    Division of Pulmonary, Allergy, and Critical Care Medicine, Department of Medicine, Duke University School of Medicine, Durham, NC 27710, USA
    J Exp Med 208:1459-71. 2011
    ..Understanding the mechanisms leading to an invasive fibroblast phenotype could lead to novel approaches to the treatment of disorders characterized by severe tissue fibrosis...
  4. ncbi Bayesian probit regression model for the diagnosis of pulmonary fibrosis: proof-of-principle
    Eric B Meltzer
    Department of Medicine, Division of Pulmonary, Allergy and Critical Care Medicine, Duke University Medical Center, Durham, North Carolina, USA
    BMC Med Genomics 4:70. 2011
    ..The accurate diagnosis of idiopathic pulmonary fibrosis (IPF) is a major clinical challenge. We developed a model to diagnose IPF by applying Bayesian probit regression (BPR) modelling to gene expression profiles of whole lung tissue...
  5. ncbi Inhibition of pulmonary fibrosis in mice by CXCL10 requires glycosaminoglycan binding and syndecan-4
    Dianhua Jiang
    Division of Pulmonary, Allergy, and Critical Care Medicine, Department of Medicine, Duke University School of Medicine, Durham, North Carolina 27710, USA
    J Clin Invest 120:2049-57. 2010
    ..Thus, administration of CXCL10 protein defective in CXCR3 binding may represent a novel therapy for pulmonary fibrosis...